Sarcopenia , as defined by reduced muscle mass alone , was found to be very prevalent in patients with lung cancer , regardless of body mass index , and where present was associated with poorer functional status and overall survival .
The effect of nutritional supplements and ATP infusions on muscle mass showed conflicting results .
There are very limited data on the correlation between degree of sarcopenia and muscle function , which has a non-linear relationship in older non-cancer population s. CONCLUSIONS Loss of muscle mass is a significant contributor to morbidity in patients with lung cancer .
OBJECTIVES There is growing awareness of the relationship between sarcopenia ( loss of muscle mass and function ) , and outcomes in cancer , making it a potential target for future therapies .
In order to inform future research and practice , we undertook a systematic review of factors associated with loss of muscle mass , and the relationship between muscle function and muscle mass in lung cancer , a common condition associated with poor outcomes .
Cysteine-rich protein reverses weight loss in lung cancer patients receiving chemotherapy or radiotherapy.
Oxidative stress plays a role in the tumor-cytotoxic effect of cancer chemotherapy and radiotherapy and also in certain adverse events . In view of these conflicting aspects , a double-blind trial over a 6-month period was performed to determine whether a cysteine-rich protein ( IMN1207 ) may have a positive or negative effect on the clinical outcome if compared with casein , a widely used protein supplement low in cysteine . Sixty-six patients with stage IIIB-IV non-small cell lung cancer were r and omly assigned to IMN1207 or casein . Included were patients with a previous involuntary weight loss of > or = 3 % , Karnofsky status > or = 70 , and an estimated survival of > 3 months . Thirty-five lung cancer patients remained on study at 6 weeks . Overall compliance was not different between treatment arms ( 42 - 44 % or 13 g/day ) . The patients treated with the cysteine-rich protein had a mean increase of 2.5 % body weight , whereas casein-treated patients lost 2.6 % ( p = 0.049 ) . Differences in secondary endpoints included an increase in survival , h and -grip force , and quality of life . Adverse events were mild or moderate . Further studies will have to show whether the positive clinical effects can be confirmed and related to specific parameters of oxidative stress in the host
Sarcopenia , as defined by reduced muscle mass alone , was found to be very prevalent in patients with lung cancer , regardless of body mass index , and where present was associated with poorer functional status and overall survival .
The effect of nutritional supplements and ATP infusions on muscle mass showed conflicting results .
There are very limited data on the correlation between degree of sarcopenia and muscle function , which has a non-linear relationship in older non-cancer population s. CONCLUSIONS Loss of muscle mass is a significant contributor to morbidity in patients with lung cancer .
OBJECTIVES There is growing awareness of the relationship between sarcopenia ( loss of muscle mass and function ) , and outcomes in cancer , making it a potential target for future therapies .
In order to inform future research and practice , we undertook a systematic review of factors associated with loss of muscle mass , and the relationship between muscle function and muscle mass in lung cancer , a common condition associated with poor outcomes .